Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protein tyrosine kinase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | protein tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Brugia malayi | Protein kinase domain containing protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma japonicum | expressed protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Loa Loa (eye worm) | TK/FAK protein kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma japonicum | expressed protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma japonicum | Protein tyrosine kinase 2 beta, putative | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Echinococcus granulosus | protein tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma mansoni | tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0015 | 0 | 0.5 |
Echinococcus multilocularis | protein tyrosine kinase | 0.0305 | 0.9877 | 1 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Loa Loa (eye worm) | TK/FAK protein kinase | 0.0309 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0216 | 0.6849 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0216 | 0.6849 | 1 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0015 | 0 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0216 | 0.6849 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0216 | 0.6849 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | pteridine reductase 1 | 0.0015 | 0 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Trichomonas vaginalis | hypothetical protein | 0.0216 | 0.6849 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0216 | 0.6849 | 1 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0216 | 0.6849 | 1 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0015 | 0 | 0.5 |
Echinococcus granulosus | protein tyrosine kinase | 0.0305 | 0.9877 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0216 | 0.6849 | 1 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0216 | 0.6849 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0305 | 0.9877 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2 nM | BindingDB_Patents: Enzyme Assay. This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.